Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfembree After Surgical Myomectomy for Uterine Fibroids
NCT05538689Phase 4Withdrawn
- Sponsor
- University of Chicago
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of relugolix + estradiol + norethindrone in Uterine Fibroids (UF), sponsored by University of Chicago. Planned start Nov 2022; status: withdrawn.
02
Drugs
relugolix + estradiol + norethindrone
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT05538689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05538689.